Business Wire

MA-IMMUTA

8.6.2022 14:00:09 CEST | Business Wire | Press release

Share
Immuta Raises $100 Million in Series E Funding

Immuta , the leader in data access and data security, today announced that it has secured $100 million in Series E funding. With this investment, Immuta will meet growing data security and privacy demands by accelerating secure data access across all cloud platforms. Only Immuta can automate access to data by discovering, securing, and monitoring data on any cloud service. The new investment brings Immuta’s total financing to date to $267 million.

Led by NightDragon , the funding round also includes new investor Snowflake Ventures , the venture capital arm of the Data Cloud company, as well as participation from existing investors Dell Technologies Capital, DFJ Growth, IAG, Intel Capital, March Capital, StepStone, Ten Eleven Ventures, and Wipro Ventures. This new infusion of capital builds upon Immuta’s record growth in 2021 , which included increasing commercial annual recurring revenue (ARR) by more than 100 percent, doubling its customer base, and continuing its global expansion into EMEA and APJ. Immuta will use the investment to accelerate product innovation, expand sales, marketing, and customer success teams to meet growing global demand, and deepen strategic partnerships within the cloud data ecosystem.

“There is a major shift in the modern data stack as organizations scale to derive value from their data more quickly, while also protecting their data assets and adhering to privacy regulations,” said Immuta CEO Matthew Carroll. “We’ve entered the next wave of the cloud data evolution where automation and security are essential to meeting modern cloud and data demands. This new funding will help propel Immuta into our next phase of growth as we continue to revolutionize cloud data access and data security.”

“As the threat landscape continues to escalate and cloud migration continues, we’re seeing increased global interest in the need for secure data access solutions,” said Dave DeWalt, former CEO of FireEye, McAfee, Documentum and now Founder and Managing Director at NightDragon. “Immuta is the clear market leader in providing secure data access, providing data teams with one universal platform to control access to data at scale. Many of the world’s top data-driven organizations – Roche, Mercedes-Benz Group, IAG, and the U.S. Army – rely on Immuta every day to quickly, safely, and efficiently share more data with more users. We’re excited to be making this investment in such a critical part of the modern data stack.”

As the market leader in data access and data security, Immuta enables organizations to discover, protect, and monitor sensitive data so that users can access it – as long as they have the rights. From startups to global enterprises, organizations are struggling to provide access to data at scale while ensuring it’s done securely and in accordance with local rules and privacy regulations. Immuta offers customers the ability to secure their data in the cloud at a more granular level and easily enforce data security policies. Immuta is rapidly expanding to address these demands, and recently announced its expansion into the Australian and New Zealand markets with the addition of new customers and new hires in the region. In 2021, Immuta further expanded its partner network of top cloud data platforms with native integrations to include Snowflake , Databricks , Amazon , Google , Azure , and Starburst .

“With this expanded partnership, enterprise customers can benefit from both Snowflake’s native data policies for data governance and Immuta’s simple, centralized, and comprehensive method for managing and automating data policy within specific workflows,” said Christian Kleinerman, Snowflake SVP of Product. “Together, customers have a solution for more seamless enforcement of data policy, ultimately allowing for more customer value. We look forward to partnering with Immuta through the next stages of its growth.”

For more information about Immuta, visit www.immuta.com . Join the Immuta conversation on LinkedIn and Twitter .

About Immuta

Immuta is the market leader in secure Data Access, providing data teams one universal platform to control access to analytical data sets in the cloud. Only Immuta can automate access to data by discovering, protecting, and monitoring data. Data-driven organizations around the world trust Immuta to speed time to data, safely share more data with more users, and mitigate the risk of data leaks and breaches. Founded in 2015, Immuta is headquartered in Boston, MA. To learn more about Immuta careers, click here .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye